Beta Drugs Reports Modest Sales Growth and Mixed Profit Results for March 2026 Quarter
1 hour agoBusiness
27LENS
2 SourcesRajasthan, India
TBNthebalanced.news

Beta Drugs Reports Modest Sales Growth and Mixed Profit Results for March 2026 Quarter

Beta Drugs reported a slight increase in standalone net sales to Rs 54.35 crore for the quarter ended March 2026, up 1.14% year-on-year, with net profit rising significantly to Rs 5.33 crore. Consolidated figures showed net sales of Rs 93.96 crore, up 0.21%, and net profit of Rs 9.05 crore, a marginal increase from the previous year. However, the full-year consolidated net profit declined by 2.22% to Rs 41.48 crore, despite a 6.20% rise in annual sales to Rs 384.83 crore.

Political Bias
0%100%0%
Sentiment
58%
AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 14 May 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 2 sources
● Left 0%● Center 100%● Right 0%

The articles focus on financial performance without political framing, presenting company-reported data on sales and profits. Both standalone and consolidated results are covered, reflecting corporate and market perspectives. There is no evident political bias, as the coverage centers on business metrics and quarterly comparisons.

Sentiment — Neutral (58/100)

The tone across the articles is neutral to mildly positive, highlighting modest sales growth and significant standalone profit increases. However, the mention of a full-year net profit decline introduces a balanced view, resulting in mixed sentiment that reflects both gains and challenges in Beta Drugs' financial performance.

How 2 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
moneycontrolBeta Drugs Standalone March 2026 Net Sales at Rs 54.35 crore, up 1.14 Y-o-Y- Moneycontrol.comCenterNeutral
businessstandardBeta Drugs consolidated net profit rises 0.22 in the March 2026 quarterCenterNeutral

Coverage timeline

businessstandard broke this story on 14 May, 12:52 pm. Other outlets followed.

  1. 1
    businessstandard14 May, 12:52 pm
    Beta Drugs consolidated net profit rises 0.22 in the March 2026 quarter
  2. 2
    moneycontrol14 May, 05:41 pm
    Beta Drugs Standalone March 2026 Net Sales at Rs 54.35 crore, up 1.14 Y-o-Y- Moneycontrol.com

Lens Score breakdown

27/100
Public interest0/100
Coverage gap100%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
Cubical Financial ServicesNTPC Green EnergyChemcrux EnterprisesBeta DrugsApollo TyresDilip Buildcon

Story context

Category
Business
Location
Rajasthan, India
Sources analysed
2
Last analysed
14 May 2026
Key entities
CroreIndian rupeeNet incomeNational Stock Exchange of IndiaApollo TyresNTPC LimitedRajasthan